Furthermore, SR9009 could inhibit prostate cancer subtype 1 (PCS1), the most lethal and aggressive PCa [16], by mediating the LXRα/FOXM1 pathway independently of REV-ERBs. Here, NR1H3 is linked to posterior cortical atrophy.